BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 9934358)

  • 1. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
    Rea TH; Sieling PA
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    de Carsalade GY; Achirafi A; Flageul B
    Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M; Berhe D
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
    Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
    Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for erythema nodosum leprosum.
    Manandhar R; LeMaster JW; Roche PW
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
    Sampaio EP; Malta AM; Sarno EN; Kaplan G
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leprosy reactions in postelimination stage: the Bangladesh experience.
    Mowla MR; Ara S; Mizanur Rahman AFM; Tripura SP; Paul S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):705-711. PubMed ID: 27859670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern of bacillary clearance in multibacillary leprosy patients with multidrug therapy.
    Kumar A; Girdhar A; Girdhar BK
    Acta Leprol; 2003; 12(3):123-8. PubMed ID: 15040703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low serum HDL-cholesterol is associated with raised tumor necrosis factor-alpha during ENL reactions.
    Memon RA; Kifayet A; Shahid F; Lateef A; Chiang J; Hussain R
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):1-11. PubMed ID: 9207748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solubilization of preformed immune complexes in sera of patients with type 1 and type 2 lepra reactions.
    Chakrabarty AK; Kashyap A; Sehgal VN; Saha K
    Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):559-65. PubMed ID: 3221112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.
    Pocaterra L; Jain S; Reddy R; Muzaffarullah S; Torres O; Suneetha S; Lockwood DN
    Am J Trop Med Hyg; 2006 May; 74(5):868-79. PubMed ID: 16687695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum.
    Schmitz V; Prata RB; Barbosa MG; Mendes MA; Brandão SS; Amadeu TP; Rodrigues LS; Ferreira H; Costa Fda M; Dos Santos JB; Pacheco Fdos S; Machado Ade M; Nery JA; Hacker Mde A; Sales AM; Pinheiro RO; Sarno EN
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004955. PubMed ID: 27556927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective decrease of M. leprae-specific IgG1 and IgG3 antibodies in leprosy patients associated with ENL.
    Kifayet A; Hussain R
    Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):105-14. PubMed ID: 8690967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous delayed-type hypersensitivity responsiveness in lepromatous and borderline lepromatous leprosy patients as determined by MULTITEST CMI.
    Walsh DS; Villahermosa LG; Balagon MV; Abalos RM; Fajardo TT; Tan EV; Cellona RV; Walsh GP
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):518-26. PubMed ID: 10774662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy.
    Rea TH
    Int J Lepr Other Mycobact Dis; 2001 Dec; 69(4):318-27. PubMed ID: 12035293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of thalidomide in the management of erythema nodosum leprosum.
    Walker SL; Waters MF; Lockwood DN
    Lepr Rev; 2007 Sep; 78(3):197-215. PubMed ID: 18035771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 1 reactions in leprosy--heterogeneity in T-cell functions related to the background leprosy type.
    Laal S; Mishra RS; Nath I
    Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):481-93. PubMed ID: 2958570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy.
    Rao TD; Rao PR
    Int J Lepr Other Mycobact Dis; 1987 Mar; 55(1):36-41. PubMed ID: 3549939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentoxifylline in the treatment of erythema nodosum leprosum.
    De Carsalade GY; Achirafi A; Flageul B
    J Dermatol; 2003 Jan; 30(1):64-8. PubMed ID: 12598712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.